Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

For example, efforts to develop drugs that mimic glucagon-like peptide 1 to treat diabetes and obesity were stalling until advances in peptide chemistry led to semaglutide and opened ... a new ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic ... better access those deeper brain structures. Finally, a few studies in ...

Semaglutide, sold under the brand names of Ozempic ... of using unverified forms of the drug and the TGA is also seeking to tighten regulations on compound pharmaceuticals to prevent the risks ...

both tirzepatide and semaglutide were declared in shortage by the FDA. During a declared shortage, state-licensed pharmacists and physicians are allowed to compound these medications if they ...

But do you know how important these amazing compounds are to your health? Antioxidants were only just discovered in the 1990s, and now we know how critical they are in protecting our bodies.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1 ...